PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Public ClinicalTrials.gov record NCT01074970. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this trial is to evaluate 2-year disease-free survival in this patient population treated with single agent cisplatin and patients treated with cisplatin in combination with Rucaparib following preoperative chemotherapy. Side effects and tolerability of this treatment in patients with residual disease following preoperative chemotherapy will also be observed and characterized.
Study identification
- NCT ID
- NCT01074970
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 135 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2010 (Type not available)
- Primary completion
- Dec 15, 2018 (Actual)
- Completion
- Dec 15, 2018 (Actual)
- Last update posted
- Sep 19, 2024
2010 – 2018
United States locations
- U.S. sites
- 27
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St. Jude Heritage Healthcare | Fullerton | California | 92835 | — |
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| Central Coast Medical Oncology Corporation | Santa Maria | California | 93454 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Memorial Cancer Institute Breast Cancer Center | Hollywood | Florida | 33021 | — |
| University of Miami, Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Fort Wayne Oncology & Hematology, Inc | Fort Wayne | Indiana | 46815 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Community Regional Cancer Center | Indianapolis | Indiana | 46256 | — |
| Horizon Oncology Research, Inc./IU Health Arnett | Lafayette | Indiana | 47905 | — |
| Monroe Medical Associates | Munster | Indiana | 46321 | — |
| Northern Indiana Cancer Research Consortium | South Bend | Indiana | 46601 | — |
| Metro Health Cancer Care | Wyoming | Michigan | 49519 | — |
| Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89128 | — |
| The Center for Cancer & Hematologic Disease | Cherry Hill | New Jersey | 08003 | — |
| Virtua Health Cancer Program | Mount Holly | New Jersey | 08060 | — |
| South Jersey Health Care | Vineland | New Jersey | 08360 | — |
| Presbyterian Medical Group | Albuquerque | New Mexico | 87110 | — |
| University of New Mexico Cancer Center: Albuquerque | Albuquerque | New Mexico | 87131 | — |
| HOPE a Women's Cancer Center | Asheville | North Carolina | 28806 | — |
| Seidman Cancer Center | Cleveland | Ohio | 44106 | — |
| Oregon Health Sciences University | Portland | Oregon | 97239 | — |
| Pinnacle Health Fox Chase Regional Cancer Center | Harrisburg | Pennsylvania | 17110 | — |
| Bux-Mont Oncology Hematology Associates (FCCC) at Grand View Hospital | Sellersville | Pennsylvania | 18960 | — |
| The West Clinic | Memphis | Tennessee | 38138 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01074970, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 19, 2024 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01074970 live on ClinicalTrials.gov.